Antibodies to watch in 2010

References

• Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharma Biotechnol 2008; 9:423 - 430
   PubMed Web of Science ®Google Scholar
• Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:4116 - 4123
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103:1807 - 1814
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009; 146:34 - 43
   PubMed Web of Science ®Google Scholar
• Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. Use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2008; 8:277 - 282
   PubMedGoogle Scholar
• Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23:4390 - 4398
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007; 18:1216 - 1223
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended 2009 http://www.faqs.org/sec-filings/091021/BIOGEN-IDEC-INC_10-Q/
   Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823 - 830
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950 - 5956
   PubMed Web of Science ®Google Scholar
• Hersh EM, Weber JS, Powderly JD, Khan K, Pavlick AC, Samlowski WE, et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J Clin Oncol 2008; 26
   PubMedGoogle Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovar?ian carcinoma patients. Proc Natl Acad Sci USA 2003; 100:4712 - 4717
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681 - 6688
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008; 105:6109 - 6114
   PubMed Web of Science ®Google Scholar
• Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007; 85:24 - 28
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007; 7:6
   PubMedGoogle Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14:320 - 368
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280 - 9290
   PubMed Web of Science ®Google Scholar
• Vogel CL, Burris HA, Limentani S, Borson R, O’Shaughnessy J, Vukelja S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. J Clin Oncol 2009; 27:15
   Web of Science ®Google Scholar
• Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97:1338 - 1343
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14:2710 - 2716
   PubMed Web of Science ®Google Scholar
• Goetsch L, Corvaïa N. Insulin-like growth factor receptor type I as a target for cancer therapy. Immunotherapy 2009; 1:265 - 279
   PubMed Web of Science ®Google Scholar
• van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9:748 - 760
   PubMed Web of Science ®Google Scholar
• Watkins DJ, Tabernero J, Schmoll HJ, Trarbach T, Ramos FJ, Hsu K, et al. A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27:15
   Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27:2516 - 2522
   PubMed Web of Science ®Google Scholar
• Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7:109 - 115
   PubMedGoogle Scholar
• Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90:985 - 990
   PubMed Web of Science ®Google Scholar
• Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175:57 - 62
   PubMed Web of Science ®Google Scholar
• Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE II, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-oncol 2008; 10:182 - 189
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Spratlin J, Eckhardt SG, Milestone B, Chiorean EG, Youssoufian H, et al. DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B. Eur J Cancer 2008; 6:16
   Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330:864 - 875
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499 - 2507
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370 - 1377
   PubMed Web of Science ®Google Scholar
• Scholz C, Wyant T, Leach T, Sankoh S, Mould DR, Patella M, et al. Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis. J Crohn Colitis 2009; 3:75 - 76
   Google Scholar
• Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066 - 1073
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168 - 1178
   PubMed Web of Science ®Google Scholar
• Human Genome Science press release. Human Genome Sciences and GlaxoSmithKline announce positive results in second of two Phase 3 trials of BenlystaTM in systemic lupus erythematosus 2009; http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce-positive-results-in-second-of-two-phase-3-trials-of-benlysta-in-systemic-lupus-erythema.html
   Google Scholar
• Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1:56 - 66
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652 - 2661
   PubMed Web of Science ®Google Scholar
• Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8:74
   PubMed Web of Science ®Google Scholar
• Petri M, Hobbs K, Gordon C, Strand V, Wallace DJ, Kelley L, et al. Clinically Meaningful Improvements with Epratuzumab (Anti-CD22 mAb Targeting B-cells) in Patients (Pts) with Moderate/Severe SLE Flares: Results from 2 Randomized Controlled Trials. Am College of Rheu 2008 Annual Meeting http://acr.confex.com/acr/2008/webprogram/Paper2790.html
   Google Scholar
• van de Linde P, Tysma OM, Medema JP, Hale G, Waldmann H, Roelen DL, et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum Immunol 2006; 67:264 - 273
   PubMed Web of Science ®Google Scholar
• Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:302 - 306
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598 - 2608
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692 - 1698
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763 - 1769
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132:166 - 173
   PubMed Web of Science ®Google Scholar
• Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57:1059 - 1068
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144:200 - 207
   PubMed Web of Science ®Google Scholar
• Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 2009; 94:1188 - 1193
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215 - 1228
   PubMed Web of Science ®Google Scholar
• Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou CC, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 1999; 49:779 - 790
   PubMed Web of Science ®Google Scholar
• Prussin C, James SP, Huber MM, Klion AD, Metcalfe DD. Pilot study of anti-IL-5 in eosinophilic gastroenteritis. J Allergy Clin Immunol 2003; 111:S275
   Google Scholar
• Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939 - 2941
   PubMed Web of Science ®Google Scholar
• Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114:1449 - 1455
   PubMed Web of Science ®Google Scholar
• Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009; 53:2879 - 2886
   PubMed Web of Science ®Google Scholar
• Weisman LE, Fischer GW, Thackray HM, Johnson KE, Schuman RF, Mandy GT, et al. Safety and pharmacokinetics of a chimeric anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 2009; 9:639 - 644
   PubMed Web of Science ®Google Scholar
• Thackray H, Lassiter H, Walsh W, Brozanski B, Steinhorn R, Dhanireddy R, et al. Phase II Randomized, Double Blind, Placebo-Controlled, Safety, Pharmacokinetics (PK), and Clinical Activity Study in Very Low Birth Weight (VLBW) Neonates of Pagibaximab, a Monoclonal Antibody for the Prevention of Staphylococcal Infection. Pediatric Academic Societies 2006 http://www.biosynexus.com/phase2a.html
   Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2001; 98:8850 - 8855
   PubMed Web of Science ®Google Scholar
• Lilly press release. Phase II data on Lilly’s antibody show it affects amyloid beta, a protein believed to be associated with Alzheimer’s disease 2008; 7 30 http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=325343
   Google Scholar
• Elan/Wyeth press release. Elan and Wyeth present encouraging results from Phase 2 clinical trial of bapineuzumab at international conference on Alzheimer’s disease 2008; 7 29 http://www.wyeth.com/irj/portal/news/archive?nav=display&navTo=/wyeth_html/home/news/pressreleases/2008/1217365320105.html
   Google Scholar
• Elan/Wyeth press release. Elan and Wyeth plan to amend bapineuzumab Phase 3 protocols 2009; 4 3 http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-pressroomarticle&ID=1272546&highlight=
   Google Scholar
• Hefti F, Mokhtarani M, Gray M, Zhao C, Chan C. RN624 (anti-NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the knee. J Pain 2006; 7:45 - 46
   Google Scholar
• Katz N, Borenstein D, Birbara C, Bramson C, Nemeth M, Smith M, et al. Tanezumab, an anti-nerve growth factor (NGF) antibody, for the treatment of chronic low back pain (CLBP) — a randomized, controlled, double-blind phase 2 trial. J Pain 2009; 10:42
   Google Scholar
• Byrd JC, O’Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13:4448 - 4455
   PubMed Web of Science ®Google Scholar